Stock Track | TransMedics Soars 8.86% After-Hours on Strong Q4 Results and Upbeat Guidance

Stock Track

02/25

TransMedics Group, Inc. (TMDX) saw its stock price surge 8.86% in after-hours trading on Tuesday, following the release of its fourth-quarter and full-year 2025 financial results.

The company reported Q4 2025 revenue of $160.8 million, representing 32% year-over-year growth and beating analyst expectations. Net income for the quarter reached $105.4 million, significantly boosted by an $83.8 million tax benefit related to the release of a valuation allowance on deferred tax assets. For the full year 2025, revenue grew 37% to $605.5 million.

TransMedics also provided strong guidance for fiscal year 2026, projecting revenue between $727 million and $757 million, representing 20% to 25% growth. The company highlighted increased utilization of its Organ Care System (OCS) with 5,139 U.S. cases completed in 2025, expansion of its aviation fleet to 22 owned aircraft, and recent FDA trial approvals as key growth drivers.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1192984784"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1192984784\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1192984784?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-25 05:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1192984784","market":"nz","top_or_hot":-1,"title":"Stock Track | TransMedics Soars 8.86% After-Hours on Strong Q4 Results and Upbeat Guidance","media":"Stock Track","content":"<p>TransMedics Group, Inc. (TMDX) saw its stock price surge 8.86% in after-hours trading on Tuesday, following the release of its fourth-quarter and full-year 2025 financial results.</p><p>The company reported Q4 2025 revenue of $160.8 million, representing 32% year-over-year growth and beating analyst expectations. Net income for the quarter reached $105.4 million, significantly boosted by an $83.8 million tax benefit related to the release of a valuation allowance on deferred tax assets. For the full year 2025, revenue grew 37% to $605.5 million.</p><p>TransMedics also provided strong guidance for fiscal year 2026, projecting revenue between $727 million and $757 million, representing 20% to 25% growth. The company highlighted increased utilization of its Organ Care System (OCS) with 5,139 U.S. cases completed in 2025, expansion of its aviation fleet to 22 owned aircraft, and recent FDA trial approvals as key growth drivers.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | TransMedics Soars 8.86% After-Hours on Strong Q4 Results and Upbeat Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | TransMedics Soars 8.86% After-Hours on Strong Q4 Results and Upbeat Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-25 05:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TransMedics Group, Inc. (TMDX) saw its stock price surge 8.86% in after-hours trading on Tuesday, following the release of its fourth-quarter and full-year 2025 financial results.</p><p>The company reported Q4 2025 revenue of $160.8 million, representing 32% year-over-year growth and beating analyst expectations. Net income for the quarter reached $105.4 million, significantly boosted by an $83.8 million tax benefit related to the release of a valuation allowance on deferred tax assets. For the full year 2025, revenue grew 37% to $605.5 million.</p><p>TransMedics also provided strong guidance for fiscal year 2026, projecting revenue between $727 million and $757 million, representing 20% to 25% growth. The company highlighted increased utilization of its Organ Care System (OCS) with 5,139 U.S. cases completed in 2025, expansion of its aviation fleet to 22 owned aircraft, and recent FDA trial approvals as key growth drivers.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TMDX","symbol_name":"Transmedics Group","start_time":0,"source_url":"","article_id":"1192984784","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1192984784","pubTimestamp":1771968831,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"TransMedics Group, Inc. (TMDX) saw its stock price surge 8.86% in after-hours trading on Tuesday, following the release of its fourth-quarter and full-year 2025 financial results.The company reported...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TMDX":"Transmedics Group"},"translate_title":"个股追踪|TransMedics盘后飙升8.86%，得益于强劲的Q4业绩和乐观的指引","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TMDX":1},"content_text":"TransMedics Group, Inc. (TMDX) saw its stock price surge 8.86% in after-hours trading on Tuesday, following the release of its fourth-quarter and full-year 2025 financial results.The company reported Q4 2025 revenue of $160.8 million, representing 32% year-over-year growth and beating analyst expectations. Net income for the quarter reached $105.4 million, significantly boosted by an $83.8 million tax benefit related to the release of a valuation allowance on deferred tax assets. For the full year 2025, revenue grew 37% to $605.5 million.TransMedics also provided strong guidance for fiscal year 2026, projecting revenue between $727 million and $757 million, representing 20% to 25% growth. The company highlighted increased utilization of its Organ Care System (OCS) with 5,139 U.S. cases completed in 2025, expansion of its aviation fleet to 22 owned aircraft, and recent FDA trial approvals as key growth drivers.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}